Disorders of Golgi homeostasis form an emerging group of genetic defects. The highly heterogeneous clinical spectrum is not explained by our current understanding of the underlying cell-biological processes in the Golgi. Therefore, uncovering genetic defects and annotating gene function are challenging. Exome sequencing in a family with three siblings affected by abnormal Golgi glycosylation revealed a homozygous missense mutation, c.92T>C (p.Leu31Ser), in coiled-coil domain containing 115 (CCDC115), the function of which is unknown. The same mutation was identified in three unrelated families, and in one family it was compound heterozygous in combination with a heterozygous deletion of CCDC115. An additional homozygous missense mutation, c.31G>T (p.Asp11Tyr), was found in a family with two affected siblings. All individuals displayed a storage-disease-like phenotype involving hepatosplenomegaly, which regressed with age, highly elevated bone-derived alkaline phosphatase, elevated aminotransferases, and elevated cholesterol, in combination with abnormal copper metabolism and neurological symptoms. Two individuals died of liver failure, and one individual was successfully treated by liver transplantation. Abnormal N-and mucin type O-glycosylation was found on serum proteins, and reduced metabolic labeling of sialic acids was found in fibroblasts, which was restored after complementation with wild-type CCDC115. PSI-BLAST homology detection revealed reciprocal homology with Vma22p, the yeast V-ATPase assembly factor located in the endoplasmic reticulum (ER). Human CCDC115 mainly localized to the ERGIC and to COPI vesicles, but not to the ER. These data, in combination with the phenotypic spectrum, which is distinct from that associated with defects in V-ATPase core subunits, suggest a more general role for CCDC115 in Golgi trafficking. Our study reveals CCDC115 deficiency as a disorder of Golgi homeostasis that can be readily identified via screening for abnormal glycosylation in plasma.
Introduction
Congenital disorders of glycosylation (CDGs) are a heterogeneous group of monogenic diseases affecting the glycosylation of proteins and lipids. Approximately 100 CDGs have been described so far, and they affect multiple glycosylation pathways. 1 CDGs with abnormal protein N-linked glycosylation can be divided into type 1 CDGs, affecting glycan assembly in the endoplasmatic reticulum (ER), and type 2 CDGs, affecting glycan modification in the Golgi apparatus. Identification of disease-associated genes in the latter group is complicated by the complexity of the Golgi apparatus and the heterogeneous phenotype of individuals with CDGs, making phenotypic clustering difficult. Type 2 CDGs can be further grouped on the basis of disease mechanism. Mutations in genes encoding for proteins directly involved in Golgi glycosylation (e.g., SLC35A1 were the first to be discovered. [2] [3] [4] Another group of type 2 CDGs are caused by disturbances in Golgi homeostasis. This group encompasses several conserved oligomeric Golgi (COG)-CDGs, TMEM165-CDG (MIM: 614726) and ATP6V0A2-CDG (MIM: 611716). The COG complex is involved in retrograde Golgi transport, and mutations lead to abnormal distribution of proteins involved in the glycosylation machinery, such as glycosyltransferases. 5 TMEM165 mutations were recently described in individuals with skeletal symptoms and linked with deficient Ca 2þ and pH homeostasis. 6, 7 ATP6V0A2 mutations were described in autosomal-recessive cutis laxa type 2 (ARCL2 [MIM: 219200]). 8 ATP6V0A2
encodes a subunit of the vacuolar H þ ATPase (V-ATPase), which is primarily responsible for acidification of organelles within the secretory pathway and endolysosomal system. 9 Fibroblasts from ARCL2-affected individuals show delayed retrograde Golgi transport, in accordance with the versatile role of the V-ATPase and its involvement in multiple cellular processes. 10, 11 Traditionally, diagnostics for protein N-glycosylation defects is performed with isoelectric focusing (IEF) of serum transferrin (Tf). This method is used to distinguish between type 1 and type 2 CDGs. 12 Additionally, IEF of serum apolipoprotein C-III (ApoC-III) can detect abnormal mucin-type O-glycosylation. 13 Recently, we described the use of a high resolution nanochip-C8 QTOF mass spectrometry method for annotation of glycan structures on intact serum Tf. 14 This method provides additional glycan information, such as loss of galactose. Here, we report the identification of pathogenic mutations in coiled-coil domain containing 115 (CCDC115 [GenBank: NM_032357.3], UCSC Genome Browser [GRCh37/hg19], chr2:131,095,506-131,099,956) in five unrelated families with abnormal N-and mucin type O-glycosylation, suggestive of a Golgi homeostasis defect.
Material and Methods

Participating Individuals
Blood and, if obtained, fibroblasts of participating individuals were sent to the Radboud University Medical Center, Translational Metabolic Laboratory, for CDG diagnostics, based on clinical suspicion for an inborn error of metabolism. All participating affected individuals or their legal representatives gave informed consent for exome sequencing. Tissue and samples were obtained in accordance with the Declaration of Helsinki.
Exome Sequencing and Interpretation
Next-generation sequencing and analysis were performed as described earlier. 15 The SureSelect Human All Exon 50 Mb Kit (v.4, Agilent) was used for exome enrichment, covering~21,000 genes. The exome library was sequenced on a 5500xl SOLiD sequencer (Life Technologies). Color space reads were iteratively mapped to the hg19 reference genome with the SOLiD LifeScope software v.2.1. We used our in-house annotation pipeline for annotation of called variants and indels. 16 Variants were excluded based on a frequency of >0.2% in our inhouse database of >1,300 exomes. Also, synonymous variants, deep intronic variants, and variants in UTRs were excluded. Quality criteria were applied and included variants called more than five times and with variation of more than 20% for heterozygous variants and 80% for homozygous variants.
Bioinformatics
Amino acid sequences of human CCDC115 and homologs of other species were aligned and visualized with Jalview v.2.8 (see Web Resources). The following accession numbers were used for the alignment in Figure 1B : GenBank: NP_115733.2 (H. sapiens); GenBank: NP_081435.1 (M. musculus); GenBank: NP_001013313. 1 (D. rerio); GenBank: NP_649550.1 (D. melanogaster); GenBank: NP_011927.1 (S. cerevisiae S288c); GenBank: NP_173500.1 (A. thaliana).
Mutation Analyses
In silico analysis was done with Alamut v.2.4.6 (Interactive Biosoftware) and the effects of mutations were predicted with SIFT, PolyPhen, and MutationTaster (see Web Resources). The Exome Aggregation Consortium (ExAC) database (see Web Resources) was used for allele frequency.
Primers (Biolegio and Sigma-Aldrich) flanked with universal M13 tags were constructed with the help of the UCSC Genome Browser, Primer3, and SNPCheck3 (see Web Resources). 17, 18 For a list of primers used, see Table S1 . Sanger sequencing was performed on DNA isolated from peripheral blood or cultured fibroblasts, according to standard protocols. DNA was amplified with a T100 ThermoCycler (Bio-Rad). An ABI 3730 DNA Analyzer (Life Technologies) was used for sequencing. Data analysis was done with Sequencher 4.8 (Gene Codes). Multiplex ligation-dependent probe amplification (MLPA) was performed as described previously. 19 In short, combinations of two adjacently annealing oligonucleotide probes were hybridized and ligated. After ligation, the common ends of the probes served as a template for PCR amplification with one primer pair, and due to the fluorescent labeling of the primer, the resulting products could be separated according to size via capillary electrophoresis on an ABI3130 Genetic Analyzer (Applied Biosystems). Fragment data were analyzed in GeneScan (Applied Biosystems). Peak heights of samples from affected individuals were compared with those from control individual probes, and ratios were calculated for all fragments (originating from CCDC115, PTPN18, and SMPD4 exons) via an Excel spreadsheet. Thresholds for deletions and duplications were set at 0.75 and 1.25 respectively, and all samples were tested at least twice. All reagents for the MLPA reaction and subsequent PCR amplification were purchased from MRC-Holland, with exception of the CCDC115, PTPN18, SMPD4, and control primers (Biolegio). Primer sequences are described in Table S1 .
Cell Culture
Skin fibroblasts from participants and healthy control individuals were cultured at 37.0 C under 5.0% CO 2 in culture medium E199, supplemented with 10% fetal calf serum, and 1%
The Table S1 for primer sequences). cDNA was sequenced and cloned into the mammalian expression vector pcDNA3.1_V5_His TOPO-TA (Life Technologies). The construct was checked via Sanger sequencing and transformed in competent E. coli. DNA was extracted with the Birnboim method and checked for correct placement of the CCDC115 strand.
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Plasmid purification was done with the Plasmid Midi Kit (QIAGEN) according to the manual. Transfection was done with FuGENE HD Transfection Reagent (Promega) on coverslips coated with poly-LLysine (Sigma) and incubated overnight in DMEM (GIBCO) with 30%-50% confluency for immunofluorescence studies. 
IEF of Tf and ApoC-III
Tf IEF was performed as previously described. 21 In short, 10 ml serum or plasma sample was added to a solution containing iron and NaHCO 3 , electrophorized on a 5-7 pH gradient gel, and incubated with 60 ml polyclonal rabbit anti-Tf antibody (Dako, #A0061). Quantification of the gel was done with Image Quant software (TotalLab). Neuraminidase treatment was performed when a Tf polymorphism was suspected as described earlier. 21 ApoC-III IEF was performed as described, but with small modifications. 13 In short, 2 ml of serum/plasma was 153 diluted with saline solution. Before electrophoresis, the gel was rehydrated in a solution containing 8 M urea. After blotting on a nitrocellulose membrane filter, the blot was washed and blocked before incubation with anti-ApoC-III (1:2,000, Rockland, #600-101-114). After incubation with the secondary anti-goat-HRP antibody (1:5,000, Thermo Scientific, #31402) and ECL reagent (Pierce), the blot was visualized on a LAS3000 imaging system (Fujifilm). Blot quantification was done with Image Quant software.
MALDI-LTQ Mass Spectrometry
Mass spectrometry of total plasma N-glycans was performed as described earlier. 22 To summarize, glycans from 10 ml plasma were cleaved with PNGaseF (NE Biolabs) and incubated overnight.
After purification on graphitized carbon SPE columns, the glycans were permethylated, purified again, and eluted in 50 ml of 75% v/v aqueous acetonitrile. The glycans were dried and resuspended in a methanol/sodium acetate mixture for spotting. Measurements were done on a vMALDI-LTQ (Thermo Scientific).
Nanochip-C8 QTOF Mass Spectrometry of Intact Tf
For high-resolution mass spectrometry of the intact Tf protein, 10 ml of serum sample was incubated with anti-Tf beads before injection, and the eluate was analyzed on a microfluidic nanoLC-C8-chip 6540 QTOF instrument (Agilent Technologies). 14 Agilent
Mass Hunter Qualitative Analysis Software B.04.00 was used for data analysis. For deconvolution of the charge distribution raw data, Agilent BioConfirm Software was used.
Metabolic Labeling with Alkyne-Tagged Modified Sugar
Metabolic labeling was performed as described before. 23 Primary skin fibroblasts were maintained in DMEM supplemented with 10% fetal bovine serum (Lonza), at 37 C under 5% CO 2 atmosphere. Fibroblasts were grown overnight on glass coverslips (12 mm diameter). Medium was then changed with pre-warmed medium containing 500 mM of alkynyl-modified sugar (ManNAl, provided by Dr. Y. Geurardel and Prof. C. Biot). Labeling lasted 8 hr or 6 hr. The labeling was stopped by fixing the cells with 4% PFA. Cells were then permeabilized in 0.5% Triton X-100 for 10 min. After washes, cells were incubated in the click chemistry buffer containing CuSO4, 5H2O-BTTAA-ascorbate-potassium phosphate, and azide-fluor 545 (Sigma, #760757). The pool of fluorescent glycoconjugates was visualized through an inverted Leica TCS-SP5 confocal microscope. Pictures were taken with the Leica Application Suite Advanced Fluorescence (LAS AF) software (Leica Microsystems). For comparison purposes, each picture was taken under the same settings. TISGolgi was used to automatically detect the Golgi area and measure the Golgi fluorescence. This homemade ImageJ plugin was developed by TISBio (see Web Resources). Three different fields of two independent experiments were examined.
Results
Clinical Phenotype
All affected individuals (see pedigrees in Figure 1A and overview in Table 1 found . Individual F3-II2 (female, born in 1989) from family F3 was the second child of unrelated French parents. She had an uncomplicated birth but developed neonatal jaundice, which was treated successfully by phototherapy. This was accompanied by elevated AT and ALP. She was hospitalized at the age of one year due to persistent moderate hypotonia. Biochemically, she had elevated AST (1,780 U/l), ALT (390 U/l), and ALP (950 U/l, with increased bone fraction). Steatosis, fibrosis, and necrotic lesions were seen on liver biopsy. During childhood, she developed PMD with hypotonia and seizures. Biochemically, elevated AT and ALP persisted. At a later age, she developed hypercholesterolemia. CDG screening showed a type 2 pattern. During her last visit at the age of twenty-five years, she still suffered from PMD, as well as additional behavioral problems such as aggressiveness, agitation, and psychotic behavior, for which she is being treated with risperidone. Her seizures persisted despite treatment with lamotrigine. Serum AT and ALP remain elevated (AST 82 U/l, ALT 76 U/l, ALP 180 U/l) and ceruloplasmin low (10 mg/dl). Individuals F4-II1 (male, born in 2002, died in 2011) and F4-II2 (female, born in 2003) are brother and sister and were born to consanguineous Turkish parents. As a neonate, individual F4-II1 showed neonatal jaundice. Progressive cholestatic liver disease was diagnosed at an early age. Due to progressive liver failure, sibling F4-II1 underwent a liver transplantation at the age of three years and ten months, and sibling F4-II2 at the age of eight years. Unfortunately, the transplant of sibling F4-II1 was rejected twice, and he died at the age of nine years. Both siblings showed mild dysmorphic features and individual F4-II1 had a mild PMD. They showed elevated AT and ALP during several check-ups (F4-II1: AST 192-669 U/l, ALT 83-308 U/l, ALP 702 U/l; F4-II2: AST 98-422 U/l, ALT 98-178 U/l, ALP 710-985 U/l). Ceruloplasmin was never measured. After liver transplantation, individual F4-II2 is doing well. Among other parameters, her AT and CDG profile have normalized.
Individual F5-II1 (female, born in 2014, died after seven months) was the only child of non-consanguineous Portuguese parents. Jaundice was noticed since the first day of life. At five months, jaundice persisted and she developed hepatosplenomegaly, failure to thrive, redundant skin, poor muscle volume, and generalized hypotonia. There were no signs of PMD. Her parents refused a liver biopsy.
Intermittent episodes of hypoglycemia and hyperammonemia ensued. Subsequently, she developed progressive cholestatic liver disease (bilirubin 41.3 mg/dl, 40% conjugated) and liver failure. Investigation showed increased ATs (AST 207-972 U/l, ALT 48-153 U/l) and ALP (850-1,031 U/l). Additional biochemical analysis revealed hypercholesterolemia (431 mg/dl) and elevated LDL-C (314 mg/dl), abnormal coagulation factors (low FVII and high FVIII, INR 0.79-3.0), and anemia (Hb 7 g/dl) with acanthocytes and 7% reticulocytes. Interestingly, a bone marrow biopsy showed dyserythropoiesis, some lipidic histiocytes, and erythrophagocytosis. Later on, generalized cell vacuolization and few erythroblasts with perinuclear deposition of iron were seen. CDG screening revealed a type 2 pattern. Liver transplantation was not attempted due to rapid deterioration with multi-organ failure and encephalopathy. She died at the age of seven months. Postmortem liver analysis revealed severe cholestatic hepatitis with complete septal fibrosis and cirrhosis.
Mutational Analyses
To uncover the genetic defect, we performed exome sequencing of individuals F1-II1 and F1-II2 from index family F1. Eight possible candidates were identified on the basis of having autosomal-recessive inheritance (Table S2) . Among these candidates was a homozygous missense variant in CCDC115 (c.92T>C [p.Leu31Ser]) ( Table 1) . We performed a profile-based method, Position-Specific Iterated (PSI)-BLAST, 25 to identify possible homologs of the candidate variants and identified Vma22p (GenBank: NP_011927.1) as the yeast homolog of CCDC115 (GenBank: NP_115733.2) in the second iteration with an E-value of 2e-14 and a reciprocal E-value of 3e-11. Vma22p is a dedicated ER-localized assembly factor of the V-ATPase. 9, 26, 27 Importantly, Vma22p and CCDC115 were found as each others' best hits. This suggests that, apart from being homologs, they are likely orthologs with overlapping functions in humans. 28 Based on the link between the V-ATPase and abnormal glycosylation, this variant was considered our most likely candidate. 7 This was further supported by homozygosity mapping, indicating a small homozygous region on chromosome 2, in which CCDC115 was located ( Figure S1 ). In silico analysis of the p.Leu31Ser substitution with SIFT, PolyPhen-2, and MutationTaster predicted pathogenicity (Table S3 ). The ExAC database showed a very low allele frequency of 8.253e-06. Sanger sequencing confirmed homozygosity for the affected individuals, heterozygosity for both parents, and homozygous wild-type sequence for a healthy sibling, confirming complete segregation in the family ( Figure 1A ). Western blotting of fibroblasts derived from individual F1-II4 demonstrated a protein level similar to that of healthy control individuals ( Figure S2 ). For individuals F2-II1 and F5-II1, exome sequencing revealed multiple genetic variants, among which was the same c.92T>C homozygous missense variant (Table 1) . Sanger sequencing for individual F2-II1 confirmed homozygosity and heterozygosity for the parents ( Figure 1A ).
For individual F5-II1, Sanger sequencing of parental DNA revealed a maternal heterozygous missense mutation and a paternal wild-type sequence ( Figure 1A ). We suspected a paternal deletion as possible explanation, given that haplotype analysis excluded non-paternity. MLPA of DNA from individual F5-II1 displayed a heterozygous deletion for all exons of CCDC115 and on the studied position in upstream PTPN18 (Table S4) . We did not observe a deletion for the position we investigated within downstream SMPD4. Segregation analysis showed that the deletion originated from the paternal allele. This complete deletion of CCDC115 is in agreement with the severe phenotype of individual F5-II1.
Sanger sequencing of additional individuals with unsolved Golgi glycosylation defects identified missense mutations in CCDC115 in individuals from two unrelated families: individual F3-II2 with the same homozygous c.92T>C mutation and siblings F4-II1 and F4-II2 with a homozygous missense mutation, c.31G>T, leading to a p.Asp11Tyr substitution ( Figure 1A and Table 1 ). The p.Asp11Tyr substitution was also predicted to be pathogenic by SIFT, PolyPhen-2, and MutationTaster (Table S3 ). The allele frequency in the ExAC database was 0. In total, we found two missense mutations and one deletion in eight individuals from five families. Tables S5 and S6. (B) MALDI-LTQ mass spectrometry profiles of total serum N-glycans of a representative healthy control individual and of individual F1-II1. An increase in hypoglycosylated glycans with loss of sialic acid (purple diamond) and galactose (yellow dot) can be seen for individual F1-II1. (C) For individual F1-II1 and his unaffected mother, nanochip-C8 QTOF mass spectra are shown for the intact Tf protein (including two attached glycans) at 79,555 amu (peak 1). Any subsequent loss of sialic acid and/or galactose can be calculated on the basis of mass difference with the main peak. Individual F1-II1 shows a reduction in sialic acid and galactose residues (peaks 2-8, see Table S7 for glycan structures). m/z, mass-to-charge ratio; amu, atomic mass units.
CCDC115 is located on the negative strand, contains five exons, and encodes coiled-coil domain containing 115 with 180 amino acids and two predicted coiled-coil domains ( Figure 1B ). Both CCDC115 missense mutations are located in the first predicted coiled-coil domain and affect highly conserved positions. CCDC115 is widespread among eukaryotes, including Arabidopsis thaliana, indicating its origin at the root of the eukaryotic tree.
Glycosylation Studies
Global defects in glycosylation can be detected by IEF of serum Tf (N-glycosylation) and serum ApoC-III (mucintype O-glycosylation). Tf has two N-glycosylation sites, and the most abundant fraction corresponds with four sialic acids. ApoC-III has one mucin-type O-linked glycan that can host one or two sialic acids. An increase in fractions associated with hyposialylated Tf or ApoC-III is indicative of abnormal N-or O-glycosylation. All individuals showed a similarly abnormal type 2 N-glycosylation profile of Tf (see Figure 2A and Table S5 for quantifications). ApoC-III IEF was abnormal for all tested individuals (see Figure 2A and Table S6 for quantifications).
We performed MALDI-LTQ mass spectrometry of total plasma N-glycans of individual F1-II1 and compared the spectrum with that of a healthy control individual. Most notably, the glycans with theoretical masses of 2,433 m/z and 2,229 m/z were increased, indicating loss of either one sialic acid (2,433 m/z) or one sialic acid plus one galactose (2,229 m/z) ( Figure 2B ).
In accordance with total plasma N-glycan analysis, nanochip-C8 QTOF mass spectrometry of intact serum Tf (79,555 amu, peak 1) showed accumulation of incomplete glycans lacking sialic acid (79,265 amu, peak 2), galactose (79,104 amu, peak 3), and additional minor isoforms lacking sialic acid and/or galactose in individual F1-II1 ( Figure 2C , peaks 4-8, see Table S7 for a list of all annotated glycan structures). This pattern is compatible with an overall detrimental effect on Golgi glycosylation. Together with abnormal O-glycosylation, these data are suggestive of a Golgi homeostasis defect and a combined disorder of Nglycosylation and mucin-type O-glycosylation.
Metabolic Labeling of Sialic Acids
We further assessed glycosylation efficiency in skin-derived fibroblasts by metabolic labeling of sialic acids with alkynetagged synthetic sugar analogs. These alkyne-tagged sialic acids are incorporated into nascent glycoproteins by the cell allowing for specific detection with fluorescently labeled azides. 23 In CCDC115-deficient individuals F1-II1 and F1-II2, the pool of glycoconjugates was located to the Golgi, and immunofluorescence signal quantification in the Golgi showed a clear reduction for all individuals, in agreement with less efficient Golgi glycosylation ( Figures 3A and 3B) . Additionally, we observed a dispersed pattern of the glycoconjugates, suggestive of dilatation of the Golgi ( Figure 3B ). To investigate whether we could rescue the phenotype of individual F1-II4, we transfected skin fibroblasts with a construct containing either a mock construct or CCDC115 wild-type sequence. As seen in Figures 3C and  3D , fibroblasts transfected with a mock construct have a non-detectable fluorescence intensity in the Golgi, in contrast to fibroblasts transfected with a construct containing wild-type CCDC115.
In addition to metabolic labeling, we stained healthy control fibroblasts and fibroblasts from affected individual F2-II1 with anti-calnexin antibody to visualize the ER ( Figure 3E ). Individual F2-II1 fibroblasts showed a dilated ER in 60% of counted cells, in comparison to 20% in healthy control fibroblasts.
Localization
To define the subcellular location of CCDC115, we constructed a pcDNA3.1-CCDC115-V5 plasmid for transient expression of C-terminally V5-tagged CCDC115 in HeLa cells. Confocal imaging revealed clear localization to the ER-Golgi intermediate compartment (ERGIC) and coat protein complex I (COPI) vesicles (Figure 4) . Also, in immortalized human hepatocytes (HepaRG), CCDC115 located to the ERGIC and COPI vesicles (data not shown). Partial co-localization was seen in both cell types with CO-PII and Golgi markers. No co-localization was seen with the ER marker PDI (Figure 4) . We conclude that CCDC115 predominantly localizes to the ER-to-Golgi region but not to the ER, in contrast to yeast Vma22p. Figure 4 . CCDC115-V5 Is Located in the ER-to-Golgi Region HeLa cells were transiently transfected with a V5-tagged CCDC115 construct and then fixed and stained with immunofluorescently labeled antibodies against V5 (green in merge) and different organelle markers (magenta in merge). Shown are representative cells stained for CCDC115-V5, organelle markers, and a merge with DAPI stain (blue), including a 3-fold magnification. Co-localization is indicated by white color in the merged channel. The graphs show the fluorescence intensity profiles along the crosssections indicated. Scale bars represent 5 mm.
Discussion
We identified CCDC115 mutations in eight individuals from five unrelated families, and we provide evidence that these mutations affect protein N-and mucin-type O-glycosylation via their effect on Golgi homeostasis. Also, we showed that CCDC115 is localized to the ER-to-Golgi region. However, the question remainswhat is the function of CCDC115 and how does its deficiency result in abnormal protein glycosylation and clinical symptoms?
Previous studies in mice suggest localization of CCDC115 to the lysosomal-endosomal system and upregulation of Ccdc115 in mouse cortical neurons after fibroblast growth factor 2 (FGF2) stimulation. 29 Overexpression of Ccdc115 in mouse embryonic fibroblasts has been shown to have a positive effect on cell proliferation. 30 Our data suggest a physiological role for CCDC115 in Golgi homeostasis, and loss-of-function mutations lead to the inability of the Golgi to perform its core functions: post-translational modification and protein secretion and sorting. A disturbance in Golgi homeostasis is indicated by the combined defect of Nand O-glycosylation. Detailed structural studies on N-glycans revealed an accumulation of incomplete glycans lacking both sialic acid and galactose. These data indicate a general disturbance in Golgi homeostasis with an effect on multiple glycosylation pathways, for example, via incorrect targeting and/or recycling of glycosyltransferases and nucleotide-sugar transporters. Previously, deficient vesicular transport has been proposed as explanation for abnormal Golgi glycosylation in COG and ATP6V0A2 defects. 5, 10 Localization of CCDC115 to, among others, COPI vesicles that are involved in ER-to-Golgi transport and sorting of cargo proteins, could indicate a similar mechanism.
Based on comparative genomics, it is likely that CCDC115 and the yeast protein Vma22p are orthologs and have, at least partially, overlapping functions. Vma22p is involved in assembly of the V-ATPase proton pump by stabilizing the V0 domain during early assembly in the ER. Vma22 knockout yeast showed diminished V-ATPase activity and destabilization of the V0 domain. 31 Possibly, mutations in CCDC115 could exert part of the effect via alteration of V-ATPase assembly or function. Vma22p exerts its function as a V-ATPase assembly factor by interacting with Vph2p (also called Vma12p [GenBank: NP_012803]) and Vma21p (GenBank: NP_011619.3). 27 In another study in this issue, we have identified TMEM199 (also known as C17orf32 [GenBank: NP_689677.1]) as the human homolog of Vph2, and recently VMA21 (GenBank: NP_001017980.1) has been described as the human homolog of Vma21p. 32, 33 Individuals with TMEM199 deficiency showed partial clinical and biochemical overlap with CCDC115-deficient individuals, although symptoms seem to be milder. TMEM199-deficient individuals presented in adolescence with a phenotype of elevated ATs and ALP, hypercholesterolemia, hepatic steatosis, and low ceruloplasmin. Profound hepatosplenomegaly and PMD, as seen in CCDC115 deficiency, were absent. Compared to known V-ATPase-associated disorders, CCDC115 deficiency (and TMEM199 deficiency) is the first that predominantly affects the liver. 34 Biochemically, ATP6V0A2 deficiency is highly similar to CCDC115 (and TMEM199) deficiency with defective N-and O-glycosylation. 10, 40 Interestingly, the most severely affected individual (F5-II1) was diagnosed with redundant skin and poor muscle volume, symptoms characteristic of ATP6V0A2 and VMA21 deficiency, respectively. This hints at a phenotypical continuum among several V-ATPase-associated disorders. The storage-disease-like phenotype of CCDC115 deficiency resembles that of lysosomal disease, such as Niemann-Pick disease type C (NPC, caused by mutations in NPC1 and NPC2 [MIM: 257220]). NPC is characterized by hepatosplenomegaly and neurologic manifestations. 41 Lysosomal accumulation of cholesterol and sphingomyelin due to impaired cholesterol trafficking is the hallmark of NPC; hence, NPC can be regarded as a cholesterol trafficking disease.
42 NPC1 and NPC2 work in conjunction with each other and are involved in the transport of cholesterol from late endosomes and lysosomes to the plasma membrane and ER. Interestingly, binding of cholesterol to NPC2 is improved in an acidic environment, and this could be a possible link between CCDC115 deficiency and NPC, given that the V-ATPase is the main acidifier of lysosomal pH. 43 Alternatively, altered trafficking of lysosomal proteins could explain the clinical resemblance. All individuals had elevated serum ALP on biochemical analysis. This was determined to be bone derived for the investigated individuals. Discrepantly high bone-derived ALP can be observed in individuals with defects of GPI anchor biosynthesis. 44, 45 However, this is not supported for CCDC115 deficiency. Trafficking of GPI-anchored proteins, which might include ALP, is suggested to occur through a COPII-dependent process from ER exit sites. 46 In Vma22p mutant yeast, trafficking of ALP to the yeast vacuole is not majorly altered. 31 However, yeast ALP is membrane bound and not a GPI-anchored protein. Treatment of yeast with bafilomycin A1, a potent V-ATPase inhibitor known to block vacuole acidification, did not show any effect on trafficking and maturation of membrane-bound yeast ALP. 47 This suggests that transport of vacuolar membrane proteins, including ALP, in yeast is independent from acidification. A study in mouse pituitary corticotrope tumor cells showed decreased trafficking of cargo proteins, independent of pH, after incubation with Concamycin A (ConA), another V-ATPase inhibitor. Although knockdown of the V-ATPase showed an overlapping phenotype with ConA treatment, this was not investigated for protein secretion. Additionally, processing of the investigated protein, PC1, begins in the trans-Golgi network and could therefore not be representative for Golgi trafficking. 48 Based on the localization of CCDC115 in the ER-to-Golgi region, it could be speculated that CCDC115 has a role in protein cargo sorting or trafficking of alkaline phosphatase in addition to a possible role in V-ATPase assembly.
In conclusion, we describe eight individuals with a type 2 CDG from five unrelated families affected by mutations in CCDC115. The phenotype consists of elevated aminotransferases and alkaline phosphatase and hepatosplenomegaly in combination with psychomotor disability, hypercholesterolemia, and hypotonia. Based on homology detection, glycosylation studies, and cellular co-localization, we propose a role for CCDC115 in Golgi homeostasis.
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